Anthony Oberle, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Boston Scientific at 25.3% of the total. Reporting peaked in 2022 at $685 and has fallen 67.7% since, to $221 in 2025. That places this record below the midpoint for urology clinicians in NE, where the typical reported total is $2,774.
Across 54 payments — averaging $39.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$533
- Palette Life Sciences, Inc.$489
- Axonics, Inc.$199
- Teleflex LLC$133
- Dendreon Pharmaceuticals LLC$114
- Verity Pharmaceuticals Inc.$96
- plus $546 from 16 others
What the payments were for
- Food & beverage$2,110100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $533 |
| Palette Life Sciences, Inc. | 3 | $489 |
| Axonics, Inc. | 3 | $199 |
| Teleflex LLC | 1 | $133 |
| Dendreon Pharmaceuticals LLC | 4 | $114 |
| Verity Pharmaceuticals Inc. | 5 | $96 |
| Sumitomo Pharma America, Inc. | 5 | $82 |
| Johnson & Johnson | 3 | $60 |
| Immunitybio, Inc. | 1 | $59 |
| Endo Pharmaceuticals Inc. | 3 | $51 |
| AbbVie | 2 | $44 |
| Urogen Pharma, Inc. | 2 | $39 |
| AstraZeneca | 2 | $36 |
| Merck | 2 | $27 |
| Calyxo, Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| 180 Medical, Inc. | 1 | $19 |
| Valencia Technologies Corporation | 1 | $17 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Olympus America Inc. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Myovant Sciences Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,110 in reported general payments places this provider in the 45th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 32 | $469,956 |
| XtandiEnzalutamide | 12 | $160,837 |
| MyrbetriqMirabegron | 128 | $72,277 |
| Abiraterone Acetate | 55 | $37,587 |
| Tamsulosin Hcl | 523 | $6,957 |
| Finasteride | 442 | $5,721 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 51 | $3,170 |
| Estradiol | 37 | $2,723 |
| Potassium Citrate ErPotassium Citrate | 26 | $1,724 |
| Valproic Acid | 13 | $1,019 |
| Levetiracetam | 13 | $956 |
| Testosterone Cypionate | 26 | $578 |
| Oxybutynin Chloride | 40 | $417 |
| Prednisone | 67 | $352 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 44 | $302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $60 | $469,95632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 79 urology providers in Nebraska.
Other urology in Omaha
- John BishayOmaha$138K
- Rebecca McCreryOmaha$71K
- Judson DaviesOmaha$67K
- Stefanie BolteOmaha$59K
- Michael FeloneyOmaha$29K
- Andrew TrainerOmaha$12K
- Stephen LeslieOmaha$12K
- Jon MortonOmaha$11K
- Brett HillOmaha$11K
- John HorganOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.